Newsroom

Clinical Relevance Forty-two seronegative cats received an initial vaccination at 8 weeks of age and a booster vaccination at 12 weeks. All cats were kept in strict isolation for 3 years after the second vaccination and then were challenged with feline calicivirus (FCV) or sequentially challenged with feline rhinotracheitis virus (FRV) followed by feline panleukopenia […]

Read more

Abstract The aim of the study was to determine the efficacy of an inactivated feline leukemia virus (FeLV) vac-cine (Versifel® FeLV, Zoetis.) compared to a recombinant FeLV vaccine (Purevax® FeLV, Merial Animal Health) in young cats, exposed under laboratory conditions to a highly virulent challenge model. The study was designed to be consistent with the general immunogenicity […]

Read more

Purpose The purpose of this study was to compare the efficacy of two commercially available feline leukemia vaccines, Nobivac® Feline 2-FeLV (inactivated whole virus vaccine) and PureVax® Recombinant FeLV (live canarypox virus-vectored vaccine) following challenge with virulent feline leukemia virus. Read More about this study here

Read more

Abstract A fraction of cats exposed to feline leukemia virus (FeLV) effectively contain virus and resist persistent antigenemia/viremia. Using real-time PCR (qPCR) to quantitate circulating viral DNA levels, previously we detected persistent FeLV DNA in blood cells of non-antigenemic cats considered to have resisted FeLV challenge. In addition, previously we used RNA qPCR to quantitate […]

Read more

The availability of feline leukaemia virus {FeLV) vaccines has added a new and important dimension to the control of this infectious agent. FeLV vaccination is a controversial issue, however, partly because of differences in the formulation between the current products, partly because of conflicting claims by vaccine manufacturers and partly because experimental trials have shown […]

Read more

Twenty young adult specific pathogen-free cats were randomly divided into two groups of 10 animals each. One group was vaccinated with two doses of feline leukemia virus vaccine according to the manufac­turer’s recommendations. All 20 cats were challenge exposed oronasally (4 times over a I-week period), beginning 3 weeks after immunization, with a virulent subgroup […]

Read more

Purpose The purpose of this study was to compare the efficacy of two commercially available feline leukemia vaccines, Nobivac® Feline 2-FeLV (inactivated whole virus vaccine) and PureVax® Recombinant FeLV (live canarypox virus-vectored vaccine) following challenge with virulent feline leukemia virus. Read More about this study here

Read more

Clinical Relevance A challenge-of-immunity study was conducted to demonstrate immunity in dogs 3 years after their second vaccination with a new multivalent, modified-live vaccine containing canine adenovirus type-2, canine parvovirus (CPV), and ca-nine distemper virus (CDV). Twenty-three seronegative pups were vaccinated at 7 and 11 weeks of age. Eighteen seronegative pups, randomized into groups of […]

Read more

Leptospirosis, a zoonotic disease of worldwide significance, is caused by spirochetes of the genus Leptospira. Leptospirosis has been thought to most commonly affect young-adult, large-breed, outdoor dogs; however, small dogs in urban areas can also contract the disease. Pathogenic serovars infecting dogs include icterohaemorrhagiae, canicola, pomona, bratislava, grippotyphosa and autumnalis. Although serovar identification is of […]

Read more

Groups of 15 laboratory-bred beagles were vaccinated and boosted with either a placebo or adjuvanted bivalent bacterin comprised of a traditional Borrelia burgdorferi strain and a unique ospA- and ospB-negative B. burgdorferi strain that expressed high levels of OspC and then challenged with B. burgdorferi-infected Ixodes scapularis ticks. The vaccinated dogs produced high titers of […]

Read more